Apex Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Apex Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$15.3M	Buy	133,700 +20,874	+19%	+$2.45M	0.34%	82
2015 Q4	$16.1M	Sell	112,826 -35,569	-24%	-$4.11M	0.36%	80
2015 Q3	$13.3M	Buy	148,395 +12,355	+9%	+$1.3M	0.3%	85
2015 Q2	$15.7M	Buy	136,040 +17,750	+15%	+$1.86M	0.33%	81
2015 Q1	$11.3M	Buy	118,290 +26,925	+29%	+$2.01M	0.27%	85
2014 Q4	$6.14M	Buy	91,365 +21,801	+31%	+$1.35M	0.16%	120
2014 Q3	$3.75M	Buy	+69,564	New	+$3.42M	0.11%	143

Other funds holding CBPO

Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ICP

Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apex Capital Management's CBPO Position: Q1 2016 in Review

Apex Capital Management increased its China Biologic Products Holdings, Inc. (CBPO) stake by 19% in Q1 2016, buying an estimated $2.45M and bringing the position to 133,700 shares worth $15.3M. The position accounts for 0.34% of the portfolio, ranked #82.

Apex Capital Management first reported a position in CBPO in Q3 2014 and has held it in 7 quarters since. The position peaked at $16.1M in Q4 2015. 131 funds tracked by Wall St. Rank hold CBPO as of Q1 2016.

Apex Capital Management held 133,700 shares of China Biologic Products Holdings, Inc. worth $15.3M as of Q1 2016.
Apex Capital Management bought 20,874 China Biologic Products Holdings, Inc. shares in Q1 2016, an estimated $2.45M.
China Biologic Products Holdings, Inc. made up 0.34% of Apex Capital Management's portfolio in Q1 2016, its #82 holding.
Apex Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2014 and has held it in 7 quarters since.
Apex Capital Management's China Biologic Products Holdings, Inc. position peaked at $16.1M in Q4 2015.
131 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.